Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections
Autor: | Ana Maria Ortega-Prieto, Cassandra Fairhead, Carl Graham, Themoula Charalampous, Harry Wilson, Stuart J. D. Neil, Jose M. Jimenez-Guardeño, Neophytos Kouphou, Thomas Lechmere, Helena Winstone, Rui Pedro Galão, Jeffrey Seow, Michael H. Malim, Isabella Huettner, Ruth E Dickenson, Liane Dupont, Rahul Batra, Jia Su, Marie Jose Lista, Adela Alcolea-Medina, Daniel Cox, Gaia Nebbia, Katie J. Doores, Luke B Snell, Jonathan D. Edgeworth, Manu Shankar-Hari, Nathalia Almeida, Sam Acors, Suzanne Pickering, Blair Merrick, Thomas J. A. Maguire, Sadie R. Hallett |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Adult
Male COVID-19 Vaccines Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) media_common.quotation_subject Antibodies Viral Neutralization Virus Article Young Adult Neutralization Tests Potency Humans COVID-19 Serotherapy media_common Aged chemistry.chemical_classification Aged 80 and over biology SARS-CoV-2 Vaccination Longevity Immunization Passive COVID-19 Middle Aged Virology Antibodies Neutralizing chemistry Immunoglobulin M Immunoglobulin G Mutation Spike Glycoprotein Coronavirus biology.protein Female Antibody Glycoprotein |
Zdroj: | medRxiv article-version (status) pre article-version (number) 1 |
Popis: | As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of a durable antibody response with cross-neutralizing activity against both current and newly emerging viral variants. Cross-neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross-neutralizing antibody response has not been fully investigated. Here, we used sera from individuals infected in wave 1 in the UK to study the long-term cross-neutralization up to 10 months post onset of symptoms (POS), as well as sera from individuals infected with the B.1.1.7 variant to compare cross-neutralizing activity profiles. We show that neutralizing antibodies with cross-neutralizing activity can be detected from wave 1 up to 10 months POS. Although neutralization of B.1.1.7 and B.1.351 is lower, the difference in neutralization potency decreases at later timepoints suggesting continued antibody maturation and improved tolerance to Spike mutations. Interestingly, we found that B.1.1.7 infection also generates a cross-neutralizing antibody response, which, although still less potent against B.1.351, can neutralize parental wave 1 virus to a similar degree as B.1.1.7. These findings have implications for the optimization of vaccines that protect against newly emerging viral variants. |
Databáze: | OpenAIRE |
Externí odkaz: |